Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE - Regional Cancer Care Associates LLC

Clinical Trials

Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE

Type of Cancer
Leukemia
Locations
Hackensack
Sponsor
Bristol-Myers Squibb
Protocol Number
CA180-406
Cancer Diagnosis
To Learn More Call
201-510-0910